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Could the next big change in cancer treatment actually be tiny? There are 
many reasons that cancer is such a difficult disease to treat. Scientists can 
either try to come up with new and better cancer medicines or they can 
find better ways for cancer patients to receive their medicines. This paper 
describes a possible new way to deliver cancer medicines using something 
called nanoparticles – tiny, tiny, sponge-like materials that have the cancer 
medicines inside. Scientists hope that nanoparticles will improve the delivery 
of the cancer medicine into tumors. By putting the medicine inside the 
nanoparticle, we can protect the healthy cells in the body from these strong 
medicines, and we might be able to use a lower dose of the medicine to treat 
the patient. This exciting technology is still being researched and improved, 
but could 1 day be used as an effective strategy to treat cancer patients.
INTRODUCTION
Although there have been many improvements in cancer treatments, cancer 
is still quite difficult to treat. One reason is because cancer medicine, called 
chemotherapy, can be quite difficult for a patient to receive. The medicines 
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are quite strong, and patients taking chemotherapy can experience side effects 
such as tiredness, hair loss, weight loss, and pain. What if we were able to use 
a special device so that a patient with cancer could get the chemotherapy only 
in the cancer cells, without harming his or her healthy cells? This is the goal 
of researchers who are developing new ways to get drugs only to the cancer 
cells. These methods of getting the drugs to the cancer cells are called drug 
delivery vehicles (DDVs). The hope is that if chemotherapy can reach only the 
cancer cells and leave healthy cells undisturbed, maybe cancer patients could 
receive a lower dose of medicine, and have fewer of the strong side effects that 
are usually experienced with chemotherapy. Some kinds of DDVs are already 
being used to treat cancer patients, and some are still being developed in the 
research lab to improve them and make sure that they are safe before they can 
be tested in humans.
A major problem facing scientists who are trying to develop good DDVs is 
figuring out how to direct them into just the cancer cells. One solution is by 
taking advantages of some properties of cancer cells that are different from 
healthy cells [1].
THE CANCER CELL
Cancer is a complicated disease that causes cells to grow in a way that is differ-
ent from normal, healthy cells. A normal cell in your body will divide until it 
becomes “old” or is damaged, when it dies in a special way called programed 
cell death. This dividing followed by programed cell death is a fine-tuned 
process that occurs in cells all over our bodies! But, cancer cells do not receive 
the signal to stop dividing, and as a result they have uncontrolled cell growth 
and can become a mass of cancer cells, called a tumor. Cells in a tumor have 
a survival advantage because tumors are often able to grow a lot of blood ves-
sels, allowing them to get nutrients and continue growing. Another way that 
cancer cells differ from normal cells is that, because they are growing so rapidly, 
they can have more molecules on their surface, called surface receptors, than 
normal cells have. These receptors can recognize specific nutrients outside the 
cell and take them inside the cell to use to continue growing.
Researchers can take advantage of these differences between tumors/cancer 
cells and normal cells to try to direct a DDV into cancer cells and avoid healthy 
cells. DDVs are able to get inside tumors more easily than they can get into 
healthy tissues because the extra blood vessels make the tumors more per-
meable to the tiny DDV, and once the DDV gets inside the tumor it will stay 
there longer (Figure 1). This means that if a DDV can safely keep a cancer 
medicine inside of itself until it arrives at the tumor, this could be the key to a 
targeted cancer therapy, where the medicine is delivered into the cancer cells 
and not into healthy cells.
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DRUG DELIVERY VEHICLES MADE FROM 
NANOPARTICLES
Based on what we know from the properties of cancer cells and tumors, 
there are several requirements for developing a DDV. First, the DDV must 
be made out of a material that should not be harmful to the person receiving 
it. Second, the DDV should be small enough to get into the tumor by way of 
the surface receptors and the blood vessels. Third, the DDV should be able 
to carry the cancer medicine inside of itself and keep it inside until it reaches 
the cancer cell, where the medicine needs to be released. A fourth require-
ment, which is not necessary for the patient but is necessary for scientists 
who want to study the DDV, is that we should be able to track the DDV in 
some way, so that we know where it goes in the body and whether it is able 
to get into the cancer cells.
In these experiments, researchers have used a type of DDV called nanoparti-
cles. Nanoparticles are very tiny particles (about 1,000 times smaller than the 
diameter of one strand of your hair!). The nanoparticles used in this study are 
made out of silica, a type of glass, and they have small pores or holes, similar 
to a sponge, so that the cancer medicine can be stored inside.
We know that the smaller the nanoparticle is, the more easily it can stay inside 
the tumor [2]. This can allow the tumor to get a high dose of the cancer medi-
cine when that medicine is released from the nanoparticle. Since the nanopar-
ticles are like small sponges, we can easily get the medicines inside of them, 
but if the medicine does not stay in the nanoparticle until the nanoparticle 
reaches the tumor, then as soon as a patient gets the dose of nanoparticles, the 
medicine would slowly start to leak out! This will not protect the healthy cells 
or help us to get a high dose of medicine directly to the tumor.
A strategy we can use to keep the medicine inside of the nanoparticles until 
they get to the tumor is to connect some molecules to the surface of the 
nanoparticles to block the little openings in the “sponge” – these molecules 
Figure 1
Images A,C. show the 
nanoparticles using a 
special microscope called 
a transmission electron 
microscope (TEM) that 
allows us to see very tiny 
objects.
The nanoparticles in A. 
are larger than the 
nanoparticles in C. Both 
nanoparticles have a 
molecule inside that 
makes them glow red 
under a special light. The 
larger nanoparticles A. 
have a more difficult time 
getting inside of the tumor 
B. However, particles that 
are smaller C. are able to 
reach the tumor and stay 
inside D. We know that 
there are more of the 
smaller nanoparticles 
inside tumor compared 
with the larger 
nanoparticles because the 
tumor in D. has a very 
strong red glow in the 
tumor.
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are called gatekeeper molecules. If we design the gatekeeper molecules, so 
that the openings in the nanoparticles are completely blocked, the medicine 
cannot leak out. We can create gatekeeper molecules that are able to change 
their shape in different conditions, so that when the nanoparticles arrive in 
the tumor, the gatekeeper molecules “open” the pores and the medicine can 
be delivered. If the gatekeeper molecules are not able to completely block the 
openings, or if they are able to change their shape before the nanoparticles 
arrive in the tumor, then some of the medicine will leak out, so it is important 
to have a well-designed gatekeeper.
One of the ways that we can change the shape of these gatekeeper molecules 
is by heating them. For this experiment, we use a special machine called an 
inductive heating machine. This machine has a special coil with an electric 
current inside, and the current creates a magnetic field around the coil. If you 
put a metal object like a screwdriver inside the coil, it can heat the metal to a 
really high temperature.
Fortunately, we do not need to heat the nanoparticles very much in order to 
get the gatekeeper molecules to change their shape! So, if we put a tiny piece 
of metal inside the nanoparticle, we can use this inductive heating machine to 
gently heat the area of the tumor, changing the shape of the gatekeeper mol-
ecules, so that the pores open and the medicine is delivered, but not heating 
it so much heat that it burns or kills cells (Figure 2).
Finally, we can make our nanoparticles fluorescent (they glow green when 
we use a special light to look at them), so that we can use a microscope to see 
where they are. This allows us to track them to see if they are able to go inside 
of the tumor.
THE EXPERIMENT
Once we were able to make complete nanoparticles with all of these qualities 
(cancer medicine inside, gatekeeper molecules on the surface, and tiny metal 
particles inside, so that we can use the inductive heating machine to release the 
medicine), we used them to test what happens inside of cancer cells. For this 
experiment, we did not use an animal or human with cancer, but instead tested 
Figure 2
The TEM allows us to see 
what the nanoparticles 
look like A.
The nanoparticles have 
holes in them (that is how 
we can put the cancer 
medicines inside!), and the 
dark spots in the middle 
of the nanoparticle are the 
tiny pieces of metal that 
we put inside. The way 
that the nanoparticles 
work, shown in B., is that 
we fill them with medicine 
(the red dots) and then 
block the holes with the 
gatekeeper molecules (the 
orange barrels). Then, 
when the nanoparticles 
get into the cancer cells, 
we can use heat to make 
the gatekeeper molecules 
move away from the 
nanoparticles, so that the 
small holes are unblocked 
and the cancer medicines 
can leak out of the 
nanoparticles and into the 
cancer cell.
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the nanoparticles on breast cancer cells that we could grow in the laboratory. 
We tried three different conditions with the breast cancer cells. We had one 
group of cells that got nanoparticles with medicine but did not get inductive 
heating, one that got nanoparticles with no medicine in them but they did 
get inductive heating, one that and one group that got nanoparticles AND 
inductive heating [3]. In Figure 3, you can see the outline of the breast cancer 
cells in gray. The yellow–green spots are our nanoparticles, and the red is the 
cancer medicine that has come out of the nanoparticles and entered into the 
cells. We hoped that when we used the complete nanoparticles as a DDV we 
would see the cancer cells dying!
When we gave the nanoparticles to the cells but did not turn on the heating 
instrument, we saw that about 5% of the breast cancer cells died (look at 
the left side of Figure 3). This means that some of the cancer medicine was 
leaking out of the nanoparticles. In the middle of Figure 3, we gave the cells 
nanoparticles with no cancer medicine inside, only the tiny metal pieces. 
When we put these cells inside the heating machine for 5 min, about 17% 
of the cells died. This means that, even without medicine, the nanoparticles 
were generating enough heat to kill some of the breast cancer cells. Finally, 
when we combined both the cancer medicine and the metal pieces and 
heated the cells, we saw that 37% of the cancer cells died. We could see the 
cancer medicine inside the cells (in red), and we could also see that the 
cells became round, which is a sign of cell death.
CONCLUSION
The experiments told us that our nanoparticle DDV is a promising start for 
delivering cancer medicines into cancer cells, but there are ways that we 
should try to improve this system. We can re-design the nanoparticles to make 
Figure 3
In this experiment, we 
used breast cancer cells 
to see what would happen 
if we put our nanoparticles 
into cancer cells.
First, we wanted to see 
how much of the cancer 
medicine (a chemotherapy 
called doxorubicin, which 
looks red under the 
microscope) would be 
able to leak out from the 
nanoparticles. So, we 
added our nanoparticles 
to the cells and waited for 
24 h. In A., you can see 
the nanoparticles as green 
spots, because we added 
a dye to the nanoparticles 
that allowed us to see 
where they go inside the 
cells, and the red is from 
the cancer medicine. As 
you can see in B., we saw 
that about 5% of the cells 
die under these 
conditions. Next, we 
wanted to see if the heat 
that we generate using our 
inductive heater is enough 
to kill the cells. In C., there 
is no red because we did 
not include the cancer 
medicine, but the green 
spots inside the cells tell 
us that the nanoparticles 
were able to go inside the 
cells. In 5 min, there was 
enough heat to kill about 
17% of the breast cancer 
cells D. even though these 
nanoparticles did not have 
any cancer medicines 
inside. This is because the 
heat produced by the tiny 
metal was enough to kill 
the cells. In the final 
experiment E., we can see 
that the nanoparticles are 
able to enter into the cells 
(the green spots inside the 
cells), and that the cancer 
medicine is able to leave 
the nanoparticles and 
enter the cell (the red 
color inside the cells). Figure 3
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sure that none of the cancer medicine is leaking out before the nanoparticles 
reach the cancer cells. We can also try to decrease the amount of time that 
we need to turn on the heating machine to find a safe zone where none of 
the cells die from the heat. While there are some other nanoparticle DDVs 
already available for use in actual cancer patients, our method still needs some 
work before it can be tested in human patients. If our nanoparticle DDV can 
be improved enough to become an option for treating cancer patients, we 
hope that these patients will experience fewer of the negative side effects of 
chemotherapy than they have when the chemotherapy is given in the usual 
way. Maybe the next big change in cancer treatment can be a small, or nano-
sized, solution!
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Figure 3 
(Continued)
We also see that the 
shape of the cancer cells 
has changed a lot. Instead 
of being long like in A,C., 
the shape of the cell has 
changed to become 
round, indicating that the 
cell is dying. In this final 
experiment, we used 
nanoparticles that had the 
cancer medicine inside 
and we turned on our 
inductive heater for 5 min 
and we see that in this 
case, about 37% of the 
cancer cells died F. Since 
we had 5% of cells dying 
from cancer medicine 
leaking out without 
heating, and 17% of cells 
dying from the heating 
(5 + 17 = 22%) we can 
see that, since 37% of 
cells died with the 
complete DDV, our 
method was able to allow 
some of the cancer 
medicine to be released 
into the cancer cells when 
they were heated, killing 
them from the inside.
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